{"id":389336,"date":"2022-12-13T00:00:00","date_gmt":"2022-12-13T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0002-2022-biopharma-axial-spondyloarthritis-disease-landscape-forecast-g7-2022\/"},"modified":"2026-04-17T11:26:54","modified_gmt":"2026-04-17T11:26:54","slug":"dlsfim0002-2022-biopharma-axial-spondyloarthritis-disease-landscape-forecast-g7-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0002-2022-biopharma-axial-spondyloarthritis-disease-landscape-forecast-g7-2022\/","title":{"rendered":"Axial Spondyloarthritis | Disease Landscape &#038; Forecast | G7 | 2022"},"content":{"rendered":"<p>The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: tumor necrosis factor-alpha (TNF-\u03b1) inhibitors (Amgen \/ Pfizer\u2019s Enbrel, AbbVie\u2019s Humira, Janssen\u2019s Remicade and Simponi \/ Simponi Aria, and UCB\u2019s Cimzia); and IL-17 inhibitors (Novartis\u2019s Cosentyx and Eli Lilly\u2019s Taltz). The TNF-\u03b1 inhibitors are the most widely prescribed biologics for AxSpA that is refractory to nonsteroidal anti-inflammatory drugs (NSAIDs). However, these agents face a competitive threat, both from the launch of cost-effective biosimilars and from the growing IL-17 class. In 2019, the FDA approved Cimzia for nonradiographic (nr)-AxSpA, marking the first FDA approval for this subpopulation, followed by both IL-17 inhibitors in June 2020. The recent approval of novel oral targeted therapies\u2014JAK inhibitors (Pfizer\u2019s Xeljanz and AbbVie\u2019s Rinvoq)\u2014for ankylosing spondylitis (AS) and the impending entry of an additional IL-17 inhibitor (UCB\u2019s bimekizumab) will further shift market dynamics.<\/p>\n<p><strong>Questions answered:<\/strong><\/p>\n<ul>\n<li>How large is the treatable AxSpA population, and how will diagnosis \/ drug-treatment rates change over time?<\/li>\n<li>What are interviewed experts\u2019 insights on current treatment options for AS and nr-AxSpA? What clinical needs remain unfulfilled?<\/li>\n<li>What pipeline products are the most promising, and what key therapies are in early-phase development?<\/li>\n<li>What are interviewed experts\u2019 opinions of the use of Xeljanz and Rinvoq for AS? What sales \/ uptake could JAK inhibitors secure in AxSpA?<\/li>\n<li>What are the drivers of and constraints in the AxSpA therapy market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Content highlights:<\/strong><\/p>\n<p>Geographies: United States, EU5, Japan<\/p>\n<p>Primary research: Approximately 30 country-specific interviews with thought-leading rheumatologists; supported by survey data collected for this and other Clarivate research.<\/p>\n<p>Epidemiology: Diagnosed prevalent cases of AxSpA by country; AS and nr-AxSpA subpopulations.<\/p>\n<p>Forecast: 10-year, annualized, drug-level sales and patient share of key AxSpA therapies through 2031, segmented by brands \/ generics and epidemiological subpopulations<\/p>\n<p>Emerging therapies: Phase III: 1 drug; Phase II: 2 drugs<\/p>\n<p><strong>Product description: <\/strong><\/p>\n<p><em>Disease Landscape &#038; Forecast<\/em> provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution enhancement <\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n<p>Additionally, Disease Landscape &#038; Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389336","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-axial-spondyloarthritis","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389336","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389336\/revisions"}],"predecessor-version":[{"id":576168,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389336\/revisions\/576168"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389336"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}